Act now to reduce impact of staffing crisisNICE backs drug for diabetic macular oedema
The National Institute for Health and Clinical Excellence has recommended ranibizumab (Lucentis) for treating visual impairment caused by diabetic macular oedema, after its manufacturer Novartis agreed to provide it at a discounted rate.
Continue reading - simply register below
It only takes two minutes to do and you'll immediately have access to our news and opinion articles and you'll be able to sign up for our newsletters.
Already registered?
To check that you are registered please enter your email address below
Not registered?
Registration is free and takes just two minutes. After you register, you'll get access to our news and opinion stories and you'll be able to sign up to our newsletters.
